Difficult conditions in the UK and postponed operations expected to affect Q2 for Coloplast
It will be hard to compare the figures in Coloplast's Q2 report with other periods, says Sydbank analyst Søren Løntoft Hansen, who expects the medtech company to be affected by difficult conditions in the UK and delayed operations.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
An uphill battle in the UK, postponed operations due to covid-19 and a difficult basis for comparison with other quarters will be some of the most important themes in Coloplast's Q2 fiscal report, according to Danish financial institution Sydbank's Chief Equity Analyst Søren Løntoft Hansen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Boston Scientific had better results in Q1 than predicted
For subscribers
